Effect on HBs antigen clearance of addition of pegylated interferon alfa-2a to nucleos(t)ide analogue therapy versus nucleos(t)ide analogue therapy alone in patients with HBe antigen-negative chronic hepatitis B and sustained undetectable plasma hepatitis

Date publication

mars 2017

Journal

The lancet. Gastroenterology & hepatology

Auteurs

Membres identifiés du Cancéropôle Est :
Pr BRONOWICKI Jean-Pierre

Tous les auteurs :
Bourlière M, Rabiega P, Ganne-Carrie N, Serfaty L, Marcellin P, Barthe Y, Thabut D, Guyader D, Hezode C, Picon M, Causse X, Leroy V, Bronowicki JP, Carrieri P, Riachi G, Rosa I, Attali P, Molina JM, Bacq Y, Tran A, Grangé JD, Zoulim F, Fontaine H, Alric L, Bertucci I, Bouvier-Alias M, Carrat F,

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/28404133

Résumé

Findings from uncontrolled studies suggest that addition of pegylated interferon in patients with HBe antigen (HBeAg)-negative chronic hepatitis B receiving nucleos(t)ide analogues with undetectable plasma hepatitis B virus (HBV) DNA might increase HBs antigen (HBsAg) clearance. We aimed to assess this strategy.

Mots clés

Adolescent, Adult, Aged, Antiviral Agents, adverse effects, DNA, Viral, blood, Drug Administration Schedule, Female, Hepatitis B Surface Antigens, blood, Hepatitis B e Antigens, blood, Hepatitis B virus, genetics, Hepatitis B, Chronic, blood, Humans, Interferon-alpha, adverse effects, Male, Middle Aged, Nucleosides, adverse effects, Nucleotides, adverse effects, Patient Reported Outcome Measures, Polyethylene Glycols, adverse effects, Recombinant Proteins, adverse effects, Young Adult

Référence

Lancet Gastroenterol Hepatol. 2017 Mar;2(3):177-188